Table of Contents

1 Study Coverage

• 1.1 Imatinib Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Imatinib Drugs Market Size Growth Rate by Product
  • 1.4.2 Capsules
  • 1.4.3 Tablets
• 1.5 Market by End User
  • 1.5.1 Global Imatinib Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospitals
  • 1.5.3 Drug Stores
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Imatinib Drugs Market Size
  • 2.1.1 Global Imatinib Drugs Revenue 2014-2025
  • 2.1.2 Global Imatinib Drugs Sales 2014-2025
• 2.2 Imatinib Drugs Growth Rate by Regions
  • 2.2.1 Global Imatinib Drugs Sales by Regions
  • 2.2.2 Global Imatinib Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Imatinib Drugs Sales by Manufacturers
  • 3.1.1 Imatinib Drugs Sales by Manufacturers
  • 3.1.2 Imatinib Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Imatinib Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Imatinib Drugs Revenue by Manufacturers
  • 3.2.1 Imatinib Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Imatinib Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Imatinib Drugs Price by Manufacturers
• 3.4 Imatinib Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Imatinib Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Imatinib Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Imatinib Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Imatinib Drugs Sales by Product
• 4.2 Global Imatinib Drugs Revenue by Product
• 4.3 Imatinib Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Imatinib Drugs Breakdown Data by End User

6 North America

• 6.1 North America Imatinib Drugs by Countries
  • 6.1.1 North America Imatinib Drugs Sales by Countries
  • 6.1.2 North America Imatinib Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Imatinib Drugs by Product
• 6.3 North America Imatinib Drugs by End User

7 Europe

• 7.1 Europe Imatinib Drugs by Countries
  • 7.1.1 Europe Imatinib Drugs Sales by Countries
  • 7.1.2 Europe Imatinib Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Imatinib Drugs by Product
• 7.3 Europe Imatinib Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Imatinib Drugs by Countries
  • 8.1.1 Asia Pacific Imatinib Drugs Sales by Countries
  • 8.1.2 Asia Pacific Imatinib Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Imatinib Drugs by Product
• 8.3 Asia Pacific Imatinib Drugs by End User

9 Central & South America

• 9.1 Central & South America Imatinib Drugs by Countries
  • 9.1.1 Central & South America Imatinib Drugs Sales by Countries
  • 9.1.2 Central & South America Imatinib Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Imatinib Drugs by Product
• 9.3 Central & South America Imatinib Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Imatinib Drugs by Countries
  • 10.1.1 Middle East and Africa Imatinib Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Imatinib Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Imatinib Drugs by Product
• 10.3 Middle East and Africa Imatinib Drugs by End User

11 Company Profiles

• 11.1 Apotex Inc.
  • 11.1.1 Apotex Inc. Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Apotex Inc. Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Apotex Inc. Imatinib Drugs Products Offered
  • 11.1.5 Apotex Inc. Recent Development
• 11.2 Novartis
  • 11.2.1 Novartis Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Novartis Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Novartis Imatinib Drugs Products Offered
  • 11.2.5 Novartis Recent Development
• 11.3 Sanofi S.A.
  • 11.3.1 Sanofi S.A. Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Sanofi S.A. Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Sanofi S.A. Imatinib Drugs Products Offered
  • 11.3.5 Sanofi S.A. Recent Development
• 11.4 Cipla Inc.
  • 11.4.1 Cipla Inc. Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Cipla Inc. Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Cipla Inc. Imatinib Drugs Products Offered
  • 11.4.5 Cipla Inc. Recent Development
• 11.5 Mylan Pharms Inc.
  • 11.5.1 Mylan Pharms Inc. Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Mylan Pharms Inc. Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Mylan Pharms Inc. Imatinib Drugs Products Offered
  • 11.5.5 Mylan Pharms Inc. Recent Development
• 11.6 Glenmark Pharmaceuticals Ltd.
  • 11.6.1 Glenmark Pharmaceuticals Ltd. Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Glenmark Pharmaceuticals Ltd. Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Glenmark Pharmaceuticals Ltd. Imatinib Drugs Products Offered
  • 11.6.5 Glenmark Pharmaceuticals Ltd. Recent Development
• 11.7 Sun Pharmaceuticals
  • 11.7.1 Sun Pharmaceuticals Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Sun Pharmaceuticals Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Sun Pharmaceuticals Imatinib Drugs Products Offered
  • 11.7.5 Sun Pharmaceuticals Recent Development
• 11.8 Actavis Generics
  • 11.8.1 Actavis Generics Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Actavis Generics Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Actavis Generics Imatinib Drugs Products Offered
  • 11.8.5 Actavis Generics Recent Development
• 11.9 Dr. Reddy's Laboratories
  • 11.9.1 Dr. Reddy's Laboratories Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Dr. Reddy's Laboratories Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Dr. Reddy's Laboratories Imatinib Drugs Products Offered
  • 11.9.5 Dr. Reddy's Laboratories Recent Development
• 11.10 Teva Pharmaceutical Industries Ltd.
  • 11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Teva Pharmaceutical Industries Ltd. Imatinib Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Teva Pharmaceutical Industries Ltd. Imatinib Drugs Products Offered
  • 11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development

12 Future Forecast

• 12.1 Imatinib Drugs Market Forecast by Regions
  • 12.1.1 Global Imatinib Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Imatinib Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Imatinib Drugs Market Forecast by Product
  • 12.2.1 Global Imatinib Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Imatinib Drugs Revenue Forecast by Product 2019-2025
• 12.3 Imatinib Drugs Market Forecast by End User
• 12.4 North America Imatinib Drugs Forecast
• 12.5 Europe Imatinib Drugs Forecast
• 12.6 Asia Pacific Imatinib Drugs Forecast
• 12.7 Central & South America Imatinib Drugs Forecast
• 12.8 Middle East and Africa Imatinib Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Imatinib Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Imatinib Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Imatinib Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Imatinib Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Imatinib Drugs in these regions.
This research report categorizes the global Imatinib Drugs market by top players/brands, region, type and end user. This report also studies the global Imatinib Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Apotex Inc.
Novartis
Sanofi S.A.
Cipla Inc.
Mylan Pharms Inc.
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.

Market size by Product
Capsules
Tablets
Market size by End User
Hospitals
Drug Stores
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Imatinib Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Imatinib Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Imatinib Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Imatinib Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Imatinib Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Imatinib Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.